Sangamo Therapeutics (SGMO) Competitors

$0.17 0.00 (0.00%)

As of 05/22/2026 03:59 PM Eastern

SGMO vs. SABS, AGEN, FBIO, DOMH, and CRIS

Should you buy Sangamo Therapeutics stock or one of its competitors? MarketBeat compares Sangamo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sangamo Therapeutics include SAB Biotherapeutics (SABS), Agenus (AGEN), Fortress Biotech (FBIO), Dominari (DOMH), and Curis (CRIS). These companies are all part of the "biotechnology" industry.

How does Sangamo Therapeutics compare to SAB Biotherapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, SAB Biotherapeutics had 12 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 12 mentions for SAB Biotherapeutics and 0 mentions for Sangamo Therapeutics. SAB Biotherapeutics' average media sentiment score of 0.85 beat Sangamo Therapeutics' score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
SAB Biotherapeutics	Positive

Sangamo Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

SAB Biotherapeutics has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. SAB Biotherapeutics' return on equity of -0.29% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Sangamo Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 3,055.48%. SAB Biotherapeutics has a consensus price target of $11.00, indicating a potential upside of 182.05%. Given Sangamo Therapeutics' higher probable upside, research analysts plainly believe Sangamo Therapeutics is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

SAB Biotherapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	1.83	-$122.93M	-$0.38	N/A
SAB Biotherapeutics	$1.32M	225.90	$13.27M	-$2.11	N/A

Summary

SAB Biotherapeutics beats Sangamo Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Agenus?

Agenus (NASDAQ:AGEN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Agenus has a net margin of 50.49% compared to Sangamo Therapeutics' net margin of -310.81%. Agenus' return on equity of -31.66% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Agenus has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.13	$120K	$1.59	1.96
Sangamo Therapeutics	$39.55M	1.83	-$122.93M	-$0.38	N/A

Agenus has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Agenus presently has a consensus target price of $14.50, indicating a potential upside of 366.24%. Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 3,055.48%. Given Sangamo Therapeutics' higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Agenus had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Agenus and 0 mentions for Sangamo Therapeutics. Agenus' average media sentiment score of 0.34 beat Sangamo Therapeutics' score of 0.00 indicating that Agenus is being referred to more favorably in the media.

Company	Overall Sentiment
Agenus	Neutral
Sangamo Therapeutics	Neutral

61.5% of Agenus shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 5.5% of Agenus shares are held by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Agenus beats Sangamo Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Fortress Biotech?

Sangamo Therapeutics (NASDAQ:SGMO) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Fortress Biotech has a net margin of 193.12% compared to Sangamo Therapeutics' net margin of -310.81%. Fortress Biotech's return on equity of 109.66% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Fortress Biotech	193.12%	109.66%	45.56%

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sangamo Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 3,055.48%. Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 520.44%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Fortress Biotech had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Fortress Biotech and 0 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 equaled Fortress Biotech'saverage media sentiment score.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Fortress Biotech	Neutral

Fortress Biotech has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	1.83	-$122.93M	-$0.38	N/A
Fortress Biotech	$63.26M	1.44	$6.82M	$3.17	0.86

Sangamo Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Summary

Fortress Biotech beats Sangamo Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Dominari?

Dominari (NASDAQ:DOMH) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Dominari has higher revenue and earnings than Sangamo Therapeutics. Dominari is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.60	-$22.43M	-$4.03	N/A
Sangamo Therapeutics	$39.55M	1.83	-$122.93M	-$0.38	N/A

Dominari has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, Dominari's average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dominari	Neutral
Sangamo Therapeutics	Neutral

Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 3,055.48%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

42.5% of Dominari shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 55.3% of Dominari shares are owned by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Summary

Sangamo Therapeutics beats Dominari on 9 of the 14 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Curis?

Sangamo Therapeutics (NASDAQ:SGMO) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Curis had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Curis and 0 mentions for Sangamo Therapeutics. Curis' average media sentiment score of 1.02 beat Sangamo Therapeutics' score of 0.00 indicating that Curis is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Curis	Positive

Sangamo Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 3,055.48%. Curis has a consensus price target of $17.00, suggesting a potential upside of 3,291.86%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Sangamo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Curis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sangamo Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Curis has a beta of 3.08, indicating that its share price is 208% more volatile than the broader market.

Curis has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	1.83	-$122.93M	-$0.38	N/A
Curis	$9.44M	2.07	-$7.58M	-$1.19	N/A

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 5.4% of Curis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Curis has a net margin of -80.29% compared to Sangamo Therapeutics' net margin of -310.81%. Curis' return on equity of 0.00% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Curis	-80.29%	N/A	-181.57%

Summary

Curis beats Sangamo Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMO vs. The Competition

Export

Metric	Sangamo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$72.21M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.40	18.74	21.22	25.66
Price / Sales	1.83	323.98	562.28	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-4.36	7.09	10.31	7.14
Net Income	-$122.93M	$24.45M	$3.57B	$335.98M
7 Day Performance	17.77%	6.38%	6.43%	4.15%
1 Month Performance	-8.31%	2.43%	3.57%	2.54%
1 Year Performance	-63.17%	62.98%	34.07%	35.06%

Sangamo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMO Sangamo Therapeutics	2.0842 of 5 stars	$0.17 flat	$5.50 +3,055.5%	-63.2%	$72.21M	$39.55M	N/A	480	Gap Down
SABS SAB Biotherapeutics	3.9312 of 5 stars	$3.56 -3.8%	$11.00 +209.0%	+115.5%	$188.52M	$1.32M	N/A	140
AGEN Agenus	2.1133 of 5 stars	$3.16 -11.7%	$14.50 +358.9%	-18.6%	$149.08M	$114.20M	1.99	440	Gap Up
FBIO Fortress Biotech	3.437 of 5 stars	$2.48 +2.9%	$17.00 +585.5%	+53.9%	$80.06M	$63.26M	0.78	170	Analyst Upgrade High Trading Volume
DOMH Dominari	0.3599 of 5 stars	$3.09 -6.9%	N/A	-29.6%	$75.08M	$123.10M	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMO) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. SABS, AGEN, FBIO, DOMH, and CRIS

How does Sangamo Therapeutics compare to SAB Biotherapeutics?

Summary

How does Sangamo Therapeutics compare to Agenus?

Summary

How does Sangamo Therapeutics compare to Fortress Biotech?

Summary

How does Sangamo Therapeutics compare to Dominari?

Summary

How does Sangamo Therapeutics compare to Curis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. SABS, AGEN, FBIO, DOMH, and CRIS

How does Sangamo Therapeutics compare to SAB Biotherapeutics?

Does the media prefer SGMO or SABS?

Which has more risk and volatility, SGMO or SABS?

Is SGMO or SABS more profitable?

Do analysts rate SGMO or SABS?

Do insiders and institutionals believe in SGMO or SABS?

Which has better earnings and valuation, SGMO or SABS?

Summary

How does Sangamo Therapeutics compare to Agenus?

Is AGEN or SGMO more profitable?

Which has preferable earnings and valuation, AGEN or SGMO?

Which has more risk and volatility, AGEN or SGMO?

Do analysts prefer AGEN or SGMO?

Does the media favor AGEN or SGMO?

Do insiders & institutionals have more ownership in AGEN or SGMO?

Summary

How does Sangamo Therapeutics compare to Fortress Biotech?

Is SGMO or FBIO more profitable?

Do institutionals and insiders believe in SGMO or FBIO?

Do analysts prefer SGMO or FBIO?

Does the media refer more to SGMO or FBIO?

Which has higher earnings and valuation, SGMO or FBIO?

Which has more volatility and risk, SGMO or FBIO?

Summary

How does Sangamo Therapeutics compare to Dominari?

Which has better earnings & valuation, DOMH or SGMO?

Which has more risk & volatility, DOMH or SGMO?

Does the media favor DOMH or SGMO?

Do analysts prefer DOMH or SGMO?

Do institutionals & insiders have more ownership in DOMH or SGMO?

Is DOMH or SGMO more profitable?

Summary

How does Sangamo Therapeutics compare to Curis?

Does the media refer more to SGMO or CRIS?

Do analysts recommend SGMO or CRIS?

Which has more volatility and risk, SGMO or CRIS?

Which has preferable earnings & valuation, SGMO or CRIS?

Do insiders & institutionals have more ownership in SGMO or CRIS?

Is SGMO or CRIS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools